Retrophin (RTRX) Tops Q1 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Retrophin Reports First Quarter 2017 Financial Results
May 4, 2017 4:01 PM EDTPhase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017
Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS
First quarter revenues rose 16 percent to $34 million
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its first quarter 2017 financial results and provided a corporate update.
End of Phase 2 meeting during the first quarter established regulatory path forward for sparsentan in focal segmental glomerulosclerosis (FSGS); protocol development for single pivotal Phase 3 trial ongoingPivotal... More